Literature DB >> 874100

The role of the liver in glucagon metabolism.

J B Jaspan, A H Huen, C G Morley, A R Moossa, A H Rubenstein.   

Abstract

Total plasma immunoreactive pancreatic glucagon (IRG) was measured in samples taken simultaneously from the proximal portal vein and superior vena cava of 26 healthy rats. The portal-peripheral ratio of IRG was 2.80+/-0.25, the portal-peripheral difference (Delta) 124+/-15 pg/ml, and percentage extraction 58+/-3. Gel filtration of paired portal and peripheral vein samples showed that reduction in the 3,500-dalton IRG component (glucagon) in peripheral samples accounted for almost all the differences, there being minimal and inconsistent changes in the high molecular weight (>40,000) fraction. The portal-peripheral ratio of the 3,500-dalton glucagon was 5.24+/-1.10, the portal-peripheral difference 130+/-33 pg/ml, and the percentage extraction 81+/-5. To study the transhepatic differences in the 9,000-dalton "proglucagon-like" material, the experiment was repeated in nine rats 24 h after bilateral nephrectomy, a procedure which increases plasma levels of this fraction. The portal-peripheral ratio for plasma IRG in these rats was 1.48+/-0.12, the portal-peripheral difference 140+/-29 pg/ml, and percentage extraction 28+/-5. Gel filtration revealed no consistent differences between portal and peripheral concentrations of the 9,000- and >40,000-dalton components, which comprised 40 and 13%, respectively, of the mean IRG level of 492+/-35 pg/ml. In contrast, there were marked differences between portal and peripheral levels of the 3,500-dalton component the ratio being 3.42+/-0.63, the portal-peripheral difference 182+/-32 pg/ml, and percentage extraction 64+/-5. Similar studies in a healthy dog, in which species there are significant circulating levels of the 9,000-dalton IRG component, confirmed the selective hepatic extraction of the 3,500-dalton fraction. We conclude that the various IRG fractions are metabolized differently by the liver, and that portal-peripheral ratios based on direct assay of plasma IRG will vary depending on the percentage glucagon immunoreactivity in each fraction; the greater the combined contribution of fractions other than the 3,500-dalton component to total plasma IRG, the lower will be the ratio. Because of the heterogeneity of circulating IRG and significant differences in the metabolism of its various components, gel filtration of plasma samples is necessary for precise quantitation of the hepatic uptake of each particular fraction.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874100      PMCID: PMC372383          DOI: 10.1172/JCI108791

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Degradation of insulin-I 131 and glucagon-I 131 and factors influencing it.

Authors:  R H WILLIAMS; J S HAY; M B TJADEN
Journal:  Ann N Y Acad Sci       Date:  1959-03-30       Impact factor: 5.691

2.  Disappearance of HGF fron insulin after liver perfusion.

Authors:  M G GOLDNER; R H JAUREGUI; S WEISENFELD
Journal:  Am J Physiol       Date:  1954-10

3.  Heterogeneity of plasma glucagon in man.

Authors:  J B Jaspan; S F Kuku; J D Locker; A Huen; D S Emmanouel; A I Katz; A H Rubenstein
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

4.  Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.

Authors:  S F Kuku; J B Jaspan; D S Emmanouel; A Zeidler; A I Katz; A H Rubenstein
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

5.  Concentrations of glucagon and the insulin:glucagon ratio in the portal and peripheral circulation.

Authors:  P Felig; R Gusberg; R Hendler; F E Gump; J M Kinney; P J Mulrow
Journal:  Proc Soc Exp Biol Med       Date:  1974-10

6.  Portal and peripheral vein immunoreactive glucagon concentrations after arginine or glucose infusions.

Authors:  W G Blackard; N C Nelson; S S Andrews
Journal:  Diabetes       Date:  1974-03       Impact factor: 9.461

7.  Hyperglucagonemia in Laennec's cirrhosis. The role of portal-systemic shunting.

Authors:  R Sherwin; P Joshi; R Hendler; P Felig; H O Conn
Journal:  N Engl J Med       Date:  1974-01-31       Impact factor: 91.245

8.  Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.

Authors:  R S Sherwin; C Bastl; F O Finkelstein; M Fisher; H Black; R Hendler; P Felig
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

9.  Hyperglucagonemia of renal failure.

Authors:  G L Bilbrey; G R Faloona; M G White; J P Knochel
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

10.  Pathogenesis and characterization of hyperglucagonemia in the uremic rat.

Authors:  D S Emmanouel; J B Jaspan; S F Kuku; A H Rubenstein; A I Katz; A H Huen
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

View more
  9 in total

1.  Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.

Authors:  A Basu; A Alzaid; S Dinneen; A Caumo; C Cobelli; R A Rizza
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

2.  Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis.

Authors:  A V Greco; F Crucitti; G Ghirlanda; R Manna; L Altomonte; A G Rebuzzi; A Bertoli
Journal:  Diabetologia       Date:  1979-07       Impact factor: 10.122

3.  Clearance of immunoreactive somatostatin by perfused rat liver.

Authors:  H Sacks; L C Terry
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

4.  Distribution of cyclic AMP phosphodiesterase in microdissected periportal and perivenous rat liver tissue with different dietary states.

Authors:  D Runge; K Jungermann
Journal:  Histochemistry       Date:  1991

5.  Glucagon metabolism in the rat.

Authors:  D S Emmanouel; J B Jaspan; A H Rubenstein; A H Huen; E Fink; A I Katz
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

6.  Consequences of ventromedial hypothalamic lesions upon insulin and glucagon secretion by subsequently isolated perfused pancreases in the rat.

Authors:  F Rohner-Jeanrenaud; B Jeanrenaud
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

7.  Hypercholesterolaemia type II: changes in plasma insulin and glucagon levels after portacaval shunt.

Authors:  J P Farriaux; A S Luyckx; M Ribet
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

8.  Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion.

Authors:  T F Tse; W E Clutter; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

9.  Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats.

Authors:  Y T Kruszynska; P D Home; K G Alberti
Journal:  Diabetologia       Date:  1985-03       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.